{"entity":{"id":"nct00002786","kind":"trial","name":"Tyrosinase-specific CD8+ T cells, gene-modified and unmodified, in metastatic melanoma (Fred Hutchinson phase 1/2)","aka":[],"tldr":"An early Seattle trial that gave people with melanoma that had spread their own T cells grown to recognise tyrosinase, a melanoma protein. It started in 1995 and the registry lists it as completed in 2006.","summary":"The registry's official title is a phase I study of cellular adoptive immunotherapy using genetically modified and unmodified autologous CD8+ tyrosinase-specific T cells for patients with metastatic melanoma; the record lists it as phase 1/2, started in October 1995 and completed in March 2006, with an estimated enrolment of 20 (ClinicalTrials.gov NCT00002786). Cassian Yee is listed as study chair, the sponsor is Fred Hutchinson Cancer Center with the National Cancer Institute as collaborator, and the interventions are aldesleukin and therapeutic T cells (ClinicalTrials.gov NCT00002786). No results are posted.","status":"completed","asOf":"2026-11-05","links":[{"label":"ClinicalTrials.gov NCT00002786","url":"https://clinicaltrials.gov/study/NCT00002786"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":["tyr"],"drugs":["aldesleukin"],"companies":[],"institutions":["fred-hutch","nci"],"pathways":[],"terms":["endogenous-t-cell-therapy"],"trials":[],"people":["cassian-yee"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo agent (Claude Opus 5.5)","editedOn":"2026-11-05","note":"Written from the MD Anderson faculty profile, ORCID, Europe PMC, ClinicalTrials.gov v2, SEC EDGAR and each organisation's own site, read on 5 November 2026."},"nct":"NCT00002786","phase":"1/2","setting":"Metastatic melanoma: autologous CD8+ tyrosinase-specific T cells, genetically modified and unmodified, with aldesleukin","sponsor":"Fred Hutchinson Cancer Center, with the National Cancer Institute","result":"No results posted on ClinicalTrials.gov.","started":"1995-10","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00002786/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"target":[{"id":"tyr","kind":"target","name":"TYR","route":"/targets/tyr/"}],"drug":[{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/"}],"institution":[{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"term":[{"id":"endogenous-t-cell-therapy","kind":"term","name":"Endogenous T-cell therapy","route":"/terms/endogenous-t-cell-therapy/"}],"person":[{"id":"cassian-yee","kind":"person","name":"Cassian Yee","route":"/people/cassian-yee/"}]}}